Venus Remedies Shares Surge on Receiving US FDA Qualified Product Status for VRP-034

Venus Remedies has created a new medicine called VRP-034, which is a unique version of the antibiotic Polymyxin B. This new version is designed to reduce kidney damage (nephrotoxicity), a major side effect of the regular Polymyxin B. The new drug uses advanced technology to make it safer while keeping it effective.

US FDA Approval and Benefits

The United States Food and Drug Administration (US FDA) has given VRP-034 a special status called “Qualified Infectious Disease Product” (QIDP). This recognition is part of the GAIN Act and offers benefits like faster approval, priority review and five extra years of exclusive marketing once approved.

Research and Development

The drug was developed by Venus Medicine Research Centre, using its special Renal Guard technology. They used modern tools like “kidney-on-a-chip” models to test and improve the medicine. These tests showed that VRP-034 caused up to 70% less kidney damage and worked well against drug-resistant bacteria.

Importance and Impact

Polymyxins, including Polymyxin B and colistin, are among the last options for treating serious infections. However, their use is limited due to kidney-related side effects. VRP-034 offers a safer solution. This US FDA recognition shows global support for better treatments and highlights Venus Remedies’ efforts to fight antibiotic resistance and improve critical care.

Share Price Performance 

As of April 17, 2025, at 11:25 AM, Venus Remedies Limited Share Price is trading at ₹337.80 per share, reflecting a surge of 8.04% from the previous day’s closing price. Over the past month, the stock has registered a profit of 15.39%. The stock’s 52-week high stands at ₹427.90 per share, while its low is ₹270.25 per share.

Conclusion

The recognition from the US FDA marks a big step for Venus Remedies. VRP-034 could change how dangerous infections are treated by offering a safer, effective solution. This development shows the company’s strong efforts in innovation and healthcare improvement.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.